The SUMO Pathway in Hematomalignancies and Their Response to Therapies

SUMO (Small Ubiquitin-related MOdifier) is a post-translational modifier of the ubiquitin family controlling the function and fate of thousands of proteins. SUMOylation is deregulated in various hematological malignancies, where it participates in both tumorigenesis and cancer cell response to thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulanger, Mathias, Paolillo, Rosa, Piechaczyk, Marc, Bossis, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721055/
https://www.ncbi.nlm.nih.gov/pubmed/31405039
http://dx.doi.org/10.3390/ijms20163895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721055/
https://www.ncbi.nlm.nih.gov/pubmed/31405039
http://dx.doi.org/10.3390/ijms20163895

Ejemplares similares